OncoResponse launched by Theraclone, MD Anderson; initiates Series A; round closes at $22.5mm
Theraclone Sciences Inc. and the MD Anderson Cancer Center have together spun out a new company, OncoResponse Inc., which will develop antibodies against immuno-oncology targets. The new entity also received $9.5mm in Series A round funding.
- Large Molecule
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.